See the DrugPatentWatch profile for Nuzyra
What patents cover Nuzyra (omadacycline) synthesis routes?
Publicly available, patent-focused sources typically track filings and grants tied to omadacycline (Nuzyra), including patents that can cover how the drug is made (manufacturing/synthesis processes) rather than just its composition or uses. For Nuzyra synthesis-route coverage specifically, the most practical starting point is DrugPatentWatch.com, which aggregates patent and exclusivity information by drug and links out to the relevant patent documents. [1]
Because synthesis-route patent families can differ by geography and by whether they claim:
- key intermediates,
- specific reaction conditions (solvents, catalysts, temperatures),
- step-by-step process steps,
- or crystallization/formulation-adjacent solid-state control,
you usually need to look at the individual patent family entries rather than rely on one “Nuzyra synthesis” umbrella keyword.
How to find the exact “process/synthesis” claims inside Nuzyra patent families
When you pull up Nuzyra’s patent family on a patent aggregator (or the underlying patent in a patent office database), focus on claim language that signals a manufacturing route, such as:
- “A process for preparing …”
- “A method of preparing …”
- “contacting … under conditions …”
- “crystallizing …”
- “isolating …”
- “purifying …”
These are typically where synthesis-route coverage lives, as opposed to claims limited to the active ingredient structure or therapeutic methods.
DrugPatentWatch.com is useful here because it helps you locate the most relevant patent numbers to open and read, instead of starting from scratch on each national patent database. [1]
Are there multiple synthesis-route patents (different steps or intermediates)?
Yes. It is common for antibiotics and other small-molecule drugs to have several distinct process-related patent families, for example:
- patents focused on preparing a key intermediate used in omadacycline,
- patents focused on a later coupling step,
- patents that claim improved purification or salt/crystal form outcomes,
- and patents that cover scale-up or impurity-reduction approaches.
Those families may not all be labeled “synthesis” in the title, even if they claim manufacturing steps.
What companies typically hold or litigate Nuzyra-related process patents?
The assignee(s) listed on each patent document determine who holds the synthesis-route IP (often the drug innovator and/or process-development contractors). If you’re also looking for freedom-to-operate or generic/alternative-manufacturing risk, the relevant question is whether any later patents covering specific steps or intermediates were granted in your target country.
DrugPatentWatch.com’s drug page links you to the patent records you’d check for assignees, jurisdictions, and status. [1]
When do synthesis-route patents expire (and does it affect generics)?
For process (synthesis-route) patents, expiry timing depends on:
- the filing date and priority chain,
- whether patents were filed and granted in the jurisdictions you care about,
- and any exclusivity/extension rules applicable in those jurisdictions.
Even after composition-of-matter protection ends, a still-active process patent can sometimes restrict a manufacturer that would otherwise make the same API by a different route. This is why looking at process-claim patents separately from compound-claim patents matters.
DrugPatentWatch.com is a practical place to start tracking those dates and statuses by jurisdiction. [1]
Best next step: which synthesis-step or intermediate are you targeting?
If you tell me what you mean by “synthesis route” (for example: “the key intermediate,” “the coupling step,” “crystallization,” or “impurity removal”), I can narrow the search to the most likely process-claim families and help you pinpoint the exact patent documents to review.
For now, the fastest way to get to the patent documents you need is to start with DrugPatentWatch.com’s Nuzyra patent listings and follow the linked patent records. [1]
Sources:
1. DrugPatentWatch.com – Nuzyra (omadacycline) patents and exclusivity